Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Vaxcell Bio Therapeutics banner
V

Vaxcell Bio Therapeutics
KOSDAQ:323990

Watchlist Manager
Vaxcell Bio Therapeutics
KOSDAQ:323990
Watchlist
Price: 9 360 KRW -4.88% Market Closed
Market Cap: ₩217.7B
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

Revenue
+
3Y
-
5Y
-
10Y
-
Operating Income
+
3Y
-124%
5Y
-
10Y
-
Net Income
+
3Y
-106%
5Y
-
10Y
-

Earnings Waterfall
Vaxcell Bio Therapeutics

Income Statement
Vaxcell Bio Therapeutics

Rotate your device to view
Income Statement
Currency: KRW
Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
35
7
15
22
27
24
21
18
17
23
27
32
44
48
119
178
225
268
246
190
Revenue
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
14
N/A
40
+194%
70
+72%
552
+694%
1 899
+244%
3 592
+89%
5 549
+54%
6 720
+21%
Gross Profit
Cost of Revenue
0
0
0
0
0
0
0
0
0
0
0
0
(7)
(20)
(33)
(413)
(1 534)
(2 929)
(4 593)
(5 672)
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
7
N/A
20
+182%
37
+82%
139
+281%
365
+162%
663
+82%
955
+44%
1 048
+10%
Operating Income
Operating Expenses
(4 255)
(5 393)
(4 765)
(6 244)
(5 904)
(6 533)
(6 664)
(7 225)
(8 213)
(8 941)
(10 165)
(11 219)
(11 514)
(12 274)
(13 431)
(13 970)
(15 402)
(16 765)
(17 247)
(17 253)
Selling, General & Administrative
(2 730)
(3 435)
(2 903)
(3 962)
(3 847)
(4 409)
(4 514)
(4 762)
(5 839)
(6 121)
(6 598)
(6 799)
(6 202)
(6 611)
(7 307)
(6 552)
(8 028)
(8 206)
(7 748)
(9 899)
Research & Development
(1 037)
(1 342)
(1 354)
(1 627)
(1 511)
(1 559)
(1 570)
(1 876)
(1 774)
(2 218)
(2 969)
(3 836)
(4 673)
(4 988)
(5 193)
(6 193)
(5 910)
(6 882)
(7 645)
(5 582)
Depreciation & Amortization
(488)
(616)
(509)
(656)
(546)
(566)
(580)
(587)
(600)
(602)
(599)
(584)
(640)
(687)
(942)
(1 236)
(1 464)
(1 713)
(1 915)
(1 834)
Other Operating Expenses
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
0
36
61
61
Operating Income
(4 255)
N/A
(5 393)
-27%
(4 765)
+12%
(6 244)
-31%
(5 904)
+5%
(6 533)
-11%
(6 664)
-2%
(7 225)
-8%
(8 213)
-14%
(8 941)
-9%
(10 165)
-14%
(11 219)
-10%
(11 507)
-3%
(12 253)
-6%
(13 394)
-9%
(13 830)
-3%
(15 038)
-9%
(16 101)
-7%
(16 292)
-1%
(16 205)
+1%
Pre-Tax Income
Interest Income Expense
75
128
197
258
295
328
306
315
405
554
676
781
973
1 537
2 037
2 456
2 211
1 956
1 367
1 304
Non-Reccuring Items
0
0
0
0
0
0
0
0
(4)
0
0
0
0
0
2
1
(16)
(1)
(3)
(67)
Gain/Loss on Disposition of Assets
0
0
0
0
(0)
(4)
0
0
(0)
0
0
0
0
0
(23)
(23)
(57)
0
0
(34)
Total Other Income
196
505
509
620
846
537
691
871
987
1 004
934
749
260
235
945
1 373
2 276
3 357
2 762
2 558
Pre-Tax Income
(3 984)
N/A
(4 760)
-19%
(4 059)
+15%
(5 367)
-32%
(4 763)
+11%
(5 672)
-19%
(5 667)
+0%
(6 039)
-7%
(6 825)
-13%
(7 383)
-8%
(8 554)
-16%
(9 689)
-13%
(10 274)
-6%
(10 482)
-2%
(10 432)
+0%
(10 023)
+4%
(10 624)
-6%
(10 789)
-2%
(12 166)
-13%
(12 444)
-2%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(4)
0
0
0
0
Income from Continuing Operations
(3 984)
(4 760)
(4 059)
(5 367)
(4 763)
(5 672)
(5 667)
(6 039)
(6 825)
(7 383)
(8 554)
(9 689)
(10 274)
(10 482)
(10 432)
(10 027)
(10 624)
(10 789)
(12 166)
(12 440)
Net Income (Common)
(3 984)
N/A
(4 760)
-19%
(4 059)
+15%
(5 367)
-32%
(4 763)
+11%
(5 672)
-19%
(5 667)
+0%
(6 039)
-7%
(6 825)
-13%
(7 383)
-8%
(8 554)
-16%
(9 689)
-13%
(10 274)
-6%
(10 482)
-2%
(10 432)
+0%
(10 027)
+4%
(10 624)
-6%
(10 789)
-2%
(12 166)
-13%
(12 440)
-2%
EPS (Diluted)
-220.57
N/A
-268.15
-22%
-201.22
+25%
-265.63
-32%
-237.49
+11%
-280.76
-18%
-280.51
+0%
-298.89
-7%
-337.82
-13%
-365.42
-8%
-423.42
-16%
-530.38
-25%
-523.77
+1%
-456.42
+13%
-454.27
+0%
-436.63
+4%
-462.98
-6%
-499.52
-8%
-524.97
-5%
-538.98
-3%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 318,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.